MyHep LVIR

MyHep LVIR Tablets Uses, Benefits and Side Effects

The combination of ledipasvir 90 mg and sofosbuvir 400 mg is considered to be one of the best options for chronic hepatitis C viral (HCV) infection. Hence, MyHep LVIR (ledipasvir + sofosbuvir) with its compelling efficacy rate (around 99%) can be used as a first-line option against HCV genotype 1, 4, 5 and 6 and HIV-1 coinfection.

Chronic hepatitis C viral infection is a condition caused by the hepatitis C virus (HCV) that affects the liver. It is a major global health concern, with an estimated 71 million people living with chronic HCV in th world. The hepatitis C virus is primarily transmitted through blood-to-blood contact, such as sharing needles, receiving contaminated blood transfusions, or less commonly, through sexual intercourse.

Chronic hepatitis C often progresses slowly and can lead to severe liver damage, cirrhosis, and even liver cancer if left untreated. However, many individuals with chronic HCV infection may not exhibit noticeable symptoms for years or even decades.

Both these molecules ledipasvir and sofosbuvir belongs to the class of direct-acting antiviral (DAA) drugs which selectively stops the growth of HCV cells by inhibiting NS5A (ledipasvir) and NS5B (sofosbuvir) proteins.

Now medicines are avilable for this desiese. These medications can treat the infection in most cases, leading to improved outcomes and reduced risk of complications.

How to take MyHep LVIR ?

Only 1 tablet of MyHep LVIR (ledipasvir + sofosbuvir) is taken once daily. In certain scenarios, ribavirin is added for difficult-to-treat patients. The tablet is swallowed orally without changing the dose. Do not miss or skip any dose, if done immediately consult the doctor.

Initial testing before starting the therapy:  Hepatitis B viral infection tests

Treatment regimen:

Note:

• Therapy-naïve: Patients without any earlier treatment
• Therapy-experienced: Patients who had a failed therapy comprising of peginterferon/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor

Warnings signs related to MyHep LVIR (ledipasvir 90mg + sofosbuvir 400mg):

Hepatitis B viral reactivation risk:

Patients must undergo rigorous testing for Hepatitis B viral (HBV) infection. The process needs to be done to check if patients have HBV reactivation.

Bradycardia:

It is equally crucial to check if patients are undergoing any sort of treatment with amiodarone. If yes, they should be tested for irregular heartbeats and immediately consulted if deemed necessary.

Other warnings:

• Kidney disease
• Undergoing dialysis
• Liver transplant
• Other liver complications

Pregnancy or breastfeeding:

• Avoid having intercourse (sex) without condoms, HCV may spread to your partner if you are under treatment
• If patients are pregnant and planning to breastfeed

Side-effects of (ledipasvir 90mg + sofosbuvir 400mg):

Severe side-effects:

• Slow heart rate (bradycardia) with symptoms like weakness, chest pain, fever, shortness of breath, dizziness, and confusion
• Hepatitis B virus reactivation

Other side-effects:

In Summary: MyHep LVIR is effective in treatment of chronic Hepatitis C

MyHep LVIR – an antiviral medication used to treat chronic Hepatitis C (a viral infection affecting the liver). It contains two active ingredients, Ledipasvir and Sofosbuvir, which work in tandem and prevent the virus from multiplying and spreading.

This combination therapy is highly effective, often achieving a cure by eliminating the virus in patients after a 12-week course. MyHep LVIR is particularly useful for patients with genotype 1 Hepatitis C, and its oral – once-daily regimen offers a effective treatment option with fewer side effects compared to traditional interferon-based therapies.

Note: These are not all possible side-effects of  (ledipasvir 90mg + sofosbuvir 400mg), please ask your doctor for more information regarding the same.